comprehensive -WSS

comprehensive

author：comprehensive 2025-10-02 22:24:30 - browse：36158

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： GOP hopefuls to address prominent, controversial group questioning what's taught in schools

WSS

Medicare says breakthrough device reimbursement rule to come by summer

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Medicare says breakthrough device reimbursement rule to come by summer

Belarusian journalist sentenced to 4 years in prison as crackdown continues

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

How to improve immunocompromised access to mAb treatments

hotspot

comprehensive

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why do we get seasonal allergies?

Hollywood unions extend contract negotiations for actors

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

Medicare details structure of new drug price negotiation program

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

New air purifier tech could be key to improving indoor air quality

Readout LOUD podcast: What to know about H5N1 bird flu

hotspot

H5N1 bird flu: what we're starting to learn about infection in cows

Sanofi strikes deal with Novavax, boosting the vaccine maker

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Medicare says breakthrough device reimbursement rule to come by summer

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Researchers on aging grapple with how to calculate biological age

entertainment

explore

entertainment

leisure time